Literature DB >> 3617396

Pathology of experimental ureaplasma mastitis in ewes.

S Kennedy, H J Ball.   

Abstract

One mammary gland of each of nine primum partum suckling ewes was inoculated with ureaplasma 8 weeks post-partum. Infected glands were swollen, hot, and painful from 16 hours post-infection. Subsequently there was agalactia and reduction in gland size. Histopathologic and ultrastructural examination indicated that the acute phase of the induced mastitis was characterized by necrosis of secretory epithelium with a neutrophil, eosinophil, and macrophage response. Subsequently there was lymphoid infiltration, acinar involution, and fibrosis. This report confirms the pathogenicity of ureaplasma for the ovine mammary gland, and is the first description of the pathologic features of ureaplasmal mastitis in sheep.

Entities:  

Mesh:

Year:  1987        PMID: 3617396     DOI: 10.1177/030098588702400403

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  4 in total

1.  Effect of MALP-2, a lipopeptide from Mycoplasma fermentans, on bone resorption in vitro.

Authors:  G Piec; J Mirkovitch; S Palacio; P F Mühlradt; R Felix
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2.

Authors:  A Kaufmann; P F Mühlradt; D Gemsa; H Sprenger
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

3.  Mycoplasmal lipopeptide MALP-2 induces the chemoattractant proteins macrophage inflammatory protein 1alpha (MIP-1alpha), monocyte chemoattractant protein 1, and MIP-2 and promotes leukocyte infiltration in mice.

Authors:  U Deiters; P F Mühlradt
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

4.  The Lipocalin2 Gene is Regulated in Mammary Epithelial Cells by NFκB and C/EBP In Response to Mycoplasma.

Authors:  Wei Zhao; Lee Bendickson; Marit Nilsen-Hamilton
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.